Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy☆☆☆
To access this article, please choose from the options below
☆ This study was conducted as a trial of the Mayo Cancer Center Research Consortium in part by Public Health Service grants CA-35431, CA-35195, and CA-52352. The content is solely the responsibility of the authors and does not necessarily represent the views of the National Cancer Institute or the National Institute of Health.
☆☆ Additional participating institutions include: Carle Cancer Center CCOP, Urbana, IL 61801 (Kendrith M. Rowland, Jr.); Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA 52403 (Martin Wiesenfeld).
PII: S0960-9776(09)00173-8
doi:10.1016/j.breast.2009.12.001
© 2009 Elsevier Ltd. All rights reserved.
